Using a paravertebral block during thoracic (VATS/RATS) surgery to reduce postoperative complications

Perioperative Paravertebral Block Reduces Postoperative Complications in Thoracic Surgery: An Observational Study

Not applicable Interventional Tongji Hospital · NCT07211529

This study will try an intraoperative paravertebral block to see if it lowers postoperative complications in adults having VATS or RATS for lung or mediastinal procedures.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment500 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorTongji Hospital Academic / other
Locations1 site (Wuhan, Hubei)
Trial IDNCT07211529 on ClinicalTrials.gov

What this trial studies

This is an observational study with retrospective and prospective components conducted at Tongji Hospital campuses, focusing on patients undergoing thoracic operations such as wedge resection, segmentectomy, lobectomy, or mediastinal surgery. Retrospectively, prior cases in which an intraoperative paravertebral block (PVB) was used will be analyzed for associations with postoperative complications. Prospectively, perioperative biomarkers (including MMP3, neutrophils, leukocytes, PCT, CRP) and clinical measures (pain and cough scores, time to first flatus and defecation) will be collected, with 30-day follow-up for postoperative complications. The study will correlate biochemical markers with clinical outcomes to explore potential prognostic relationships.

Who should consider this trial

Good fit: Adults aged 18 or older scheduled for VATS or RATS (wedge resection, segmentectomy, lobectomy, or mediastinal surgery) who can give informed consent and are treated by anesthesiologists trained in ultrasound-guided PVB.

Not a fit: Patients converted to open thoracotomy, with prior ipsilateral thoracic surgery, who do not complete the planned surgery, or who are lost to follow-up are unlikely to receive benefit from participation or from study findings.

Why it matters

Potential benefit: If successful, using intraoperative paravertebral block could reduce postoperative complications and speed recovery after thoracic minimally invasive surgery.

How similar studies have performed: Prior randomized and observational studies have shown PVB reduces postoperative pain and opioid use and some suggest fewer pulmonary complications, but results vary and definitive evidence on complication reduction is still limited.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male or female participants aged 18 years or older.
2. Scheduled to undergo thoracic surgery via Video-Assisted Thoracoscopic Surgery (VATS) or Robotic-Assisted Thoracoscopic Surgery (RATS), including wedge resection, segmentectomy, lobectomy, or mediastinal surgery.
3. Signed informed consent obtained prior to study participation. -

Exclusion Criteria:

1. Patients who refuse to provide informed consent.
2. Anesthesiologists who have not received training in ultrasound-guided paravertebral block (PVB-US).
3. History of ipsilateral thoracic surgery.
4. Conversion to open thoracotomy during the procedure.
5. Patients who did not complete the scheduled surgery due to disease progression or medical reasons.
6. Patients who are lost to follow-up or refuse postoperative follow-up. -

Where this trial is running

Wuhan, Hubei

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Video-assisted Thoracoscopic SurgeryLung CancerPulmonary InfectionsRespiratory Failure Without HypercapniaPleural Effusion Due to Another DisorderAtelectasisBronchospasmPneumothorax
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.